You are here:

anidulafungin (Ecalta)

Advice

Following a re-submission

anidulafungin (Ecalta®) is accepted for restricted use within NHS Scotland for the treatment of invasive candidiasis in adult non-neutropenic patients.

Anidulafungin has been shown to be at least as effective as an alternative antifungal in a study of patients, the majority of whom had candidaemia. Its use is restricted to patients who are unable to tolerate fluconazole or have invasive candidiasis that is resistant to fluconazole.

Drug Details

Drug Name: anidulafungin (Ecalta)
SMC Drug ID: 465/08
Manufacturer: Pfizer Ltd
Indication: Invasive candidiasis in adult non-neutropenic patients
BNF Category:
Sub Category: 5.2 Antifungal Drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 10 November 2008

Archived Advice

Full submission 9 June 2008

Back